iRegene Secures Over RMB 300 Million in Series B+ Financing Despite Challenging Market Conditions, with CEC Capital as Exclusive Financial Advisor

iRegene, a biotech company committed to becoming a global leader in universal chemically induced cell therapies, recently announced the successful completion of its Series B+ financing round. The round was jointly led by Northern Light Venture Capital, ChuangJing Capital, Yuanxi Haihe, and other prominent investors.

CEC Capital served as the exclusive financial advisor for this transaction.

In just a few months, iRegene has completed multiple rounds of significant financing, raising a total of over RMB 300 million. This represents the largest fundraising in China's iPSC (induced pluripotent stem cell) sector in recent years, underscoring the investment community’s strong confidence in and recognition of iRegene’s leadership in the industry.

Proceeds from this round will be used to accelerate the global clinical development of iRegene’s Parkinson’s disease cell therapy candidates, NouvNeu001 and NouvNeu003, as well as its ophthalmology candidate NouvSight001. The capital will also support the expansion of the company’s early-stage R&D pipeline, strengthen its clinical and regulatory teams, and enhance industrialization capabilities.